Cargando…
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
PURPOSE: Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed in the tumor microenvironment of many solid cancers. FAP-2286 is a FAP-binding peptide coupled to a radionuclide chelator that is currently being inve...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399058/ https://www.ncbi.nlm.nih.gov/pubmed/35608703 http://dx.doi.org/10.1007/s00259-022-05842-5 |
_version_ | 1784772438515515392 |
---|---|
author | Zboralski, Dirk Hoehne, Aileen Bredenbeck, Anne Schumann, Anne Nguyen, Minh Schneider, Eberhard Ungewiss, Jan Paschke, Matthias Haase, Christian von Hacht, Jan L. Kwan, Tanya Lin, Kevin K. Lenore, Jan Harding, Thomas C. Xiao, Jim Simmons, Andrew D. Mohan, Ajay-Mohan Beindorff, Nicola Reineke, Ulrich Smerling, Christiane Osterkamp, Frank |
author_facet | Zboralski, Dirk Hoehne, Aileen Bredenbeck, Anne Schumann, Anne Nguyen, Minh Schneider, Eberhard Ungewiss, Jan Paschke, Matthias Haase, Christian von Hacht, Jan L. Kwan, Tanya Lin, Kevin K. Lenore, Jan Harding, Thomas C. Xiao, Jim Simmons, Andrew D. Mohan, Ajay-Mohan Beindorff, Nicola Reineke, Ulrich Smerling, Christiane Osterkamp, Frank |
author_sort | Zboralski, Dirk |
collection | PubMed |
description | PURPOSE: Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed in the tumor microenvironment of many solid cancers. FAP-2286 is a FAP-binding peptide coupled to a radionuclide chelator that is currently being investigated in patients as an imaging and therapeutic agent. The potency, selectivity, and efficacy of FAP-2286 were evaluated in preclinical studies. METHODS: FAP expression analysis was performed by immunohistochemistry and autoradiography on primary human cancer specimens. FAP-2286 was assessed in biochemical and cellular assays and in in vivo imaging and efficacy studies, and was further evaluated against FAPI-46, a small molecule–based FAP-targeting agent. RESULTS: Immunohistochemistry confirmed elevated levels of FAP expression in multiple tumor types including pancreatic, breast, and sarcoma, which correlated with FAP binding by FAP-2286 autoradiography. FAP-2286 and its metal complexes demonstrated high affinity to FAP recombinant protein and cell surface FAP expressed on fibroblasts. Biodistribution studies in mice showed rapid and persistent uptake of (68)Ga-FAP-2286, (111)In-FAP-2286, and (177)Lu-FAP-2286 in FAP-positive tumors, with renal clearance and minimal uptake in normal tissues. (177)Lu-FAP-2286 exhibited antitumor activity in FAP-expressing HEK293 tumors and sarcoma patient-derived xenografts, with no significant weight loss. In addition, FAP-2286 maintained longer tumor retention and suppression in comparison to FAPI-46. CONCLUSION: In preclinical models, radiolabeled FAP-2286 demonstrated high tumor uptake and retention, as well as potent efficacy in FAP-positive tumors. These results support clinical development of (68)Ga-FAP-2286 for imaging and (177)Lu-FAP-2286 for therapeutic use in a broad spectrum of FAP-positive tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05842-5. |
format | Online Article Text |
id | pubmed-9399058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-93990582022-08-25 Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy Zboralski, Dirk Hoehne, Aileen Bredenbeck, Anne Schumann, Anne Nguyen, Minh Schneider, Eberhard Ungewiss, Jan Paschke, Matthias Haase, Christian von Hacht, Jan L. Kwan, Tanya Lin, Kevin K. Lenore, Jan Harding, Thomas C. Xiao, Jim Simmons, Andrew D. Mohan, Ajay-Mohan Beindorff, Nicola Reineke, Ulrich Smerling, Christiane Osterkamp, Frank Eur J Nucl Med Mol Imaging Original Article PURPOSE: Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed in the tumor microenvironment of many solid cancers. FAP-2286 is a FAP-binding peptide coupled to a radionuclide chelator that is currently being investigated in patients as an imaging and therapeutic agent. The potency, selectivity, and efficacy of FAP-2286 were evaluated in preclinical studies. METHODS: FAP expression analysis was performed by immunohistochemistry and autoradiography on primary human cancer specimens. FAP-2286 was assessed in biochemical and cellular assays and in in vivo imaging and efficacy studies, and was further evaluated against FAPI-46, a small molecule–based FAP-targeting agent. RESULTS: Immunohistochemistry confirmed elevated levels of FAP expression in multiple tumor types including pancreatic, breast, and sarcoma, which correlated with FAP binding by FAP-2286 autoradiography. FAP-2286 and its metal complexes demonstrated high affinity to FAP recombinant protein and cell surface FAP expressed on fibroblasts. Biodistribution studies in mice showed rapid and persistent uptake of (68)Ga-FAP-2286, (111)In-FAP-2286, and (177)Lu-FAP-2286 in FAP-positive tumors, with renal clearance and minimal uptake in normal tissues. (177)Lu-FAP-2286 exhibited antitumor activity in FAP-expressing HEK293 tumors and sarcoma patient-derived xenografts, with no significant weight loss. In addition, FAP-2286 maintained longer tumor retention and suppression in comparison to FAPI-46. CONCLUSION: In preclinical models, radiolabeled FAP-2286 demonstrated high tumor uptake and retention, as well as potent efficacy in FAP-positive tumors. These results support clinical development of (68)Ga-FAP-2286 for imaging and (177)Lu-FAP-2286 for therapeutic use in a broad spectrum of FAP-positive tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05842-5. Springer Berlin Heidelberg 2022-05-24 2022 /pmc/articles/PMC9399058/ /pubmed/35608703 http://dx.doi.org/10.1007/s00259-022-05842-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Zboralski, Dirk Hoehne, Aileen Bredenbeck, Anne Schumann, Anne Nguyen, Minh Schneider, Eberhard Ungewiss, Jan Paschke, Matthias Haase, Christian von Hacht, Jan L. Kwan, Tanya Lin, Kevin K. Lenore, Jan Harding, Thomas C. Xiao, Jim Simmons, Andrew D. Mohan, Ajay-Mohan Beindorff, Nicola Reineke, Ulrich Smerling, Christiane Osterkamp, Frank Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy |
title | Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy |
title_full | Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy |
title_fullStr | Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy |
title_full_unstemmed | Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy |
title_short | Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy |
title_sort | preclinical evaluation of fap-2286 for fibroblast activation protein targeted radionuclide imaging and therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399058/ https://www.ncbi.nlm.nih.gov/pubmed/35608703 http://dx.doi.org/10.1007/s00259-022-05842-5 |
work_keys_str_mv | AT zboralskidirk preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT hoehneaileen preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT bredenbeckanne preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT schumannanne preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT nguyenminh preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT schneidereberhard preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT ungewissjan preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT paschkematthias preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT haasechristian preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT vonhachtjanl preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT kwantanya preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT linkevink preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT lenorejan preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT hardingthomasc preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT xiaojim preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT simmonsandrewd preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT mohanajaymohan preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT beindorffnicola preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT reinekeulrich preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT smerlingchristiane preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy AT osterkampfrank preclinicalevaluationoffap2286forfibroblastactivationproteintargetedradionuclideimagingandtherapy |